A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

NCT05246137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2646

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Acute Respiratory Disease

Interventions

BIOLOGICAL: COVID-19 Vaccine 40 ug/dose

Sponsor

Hipra Scientific, S.L.U